<scp>HB</scp>eAg‐positive hepatitis delta: virological patterns and clinical long‐term outcome

Heidrich, B.; Serrano, B. Calle; İdilman, Ramazan; Kabaçam, Gökhan; Bremer, Birgit; Raupach, R.; Önder, Fatih; Deterding, Katja; Zacher, Behrend J.; Taranta, Andrzej; Bozkaya, Hakan; Zachou, Kalliopi; Tillmann, Hans L.; Bozdayı, A. Mithat; Manns, Michael P.; Yurdaydın, Cihan; Wedemeyer, Heiner

doi:10.1111/j.1478-3231.2012.02831.x

Cited by 59 publications

(60 citation statements)

References 46 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with data reported by Heidrich et al [25]. Our study also demonstrated that qHBsAg levels were higher in HBeAg positive patients the despite the presence of HDV infection.…”

Section: Discussionsupporting

confidence: 94%

“…They revealed that the positivity of HBeAg does not influence either HBV-DNA level or the long-term clinical outcome of patients with chronic HDV [25]. Also, HDV-RNA and qHBsAg levels in HBeAg positive or negative groups were not significantly different [25]. In our study, 9 out of 56 (16.1%) HDV positive HBsAg carriers were detectable for HBeAg vs. 13 out of 56 (23.2%) HDV negative patients.…”

Section: Discussioncontrasting

confidence: 42%

“…Recently, HBeAg positive HDV infections were reported by German researchers from the large European cohort which compared 71 HBeAg positive HDV patients with 450 HBeAg negative HDV patients [25]. They revealed that the positivity of HBeAg does not influence either HBV-DNA level or the long-term clinical outcome of patients with chronic HDV [25]. Also, HDV-RNA and qHBsAg levels in HBeAg positive or negative groups were not significantly different [25].…”

Section: Discussionmentioning

confidence: 99%

“…HBeAg is known as a marker for HBV replication and associated with increased risk of liver cirrhosis and HCC in HBV mono infected patients [23,24]. Recently, HBeAg positive HDV infections were reported by German researchers from the large European cohort which compared 71 HBeAg positive HDV patients with 450 HBeAg negative HDV patients [25]. They revealed that the positivity of HBeAg does not influence either HBV-DNA level or the long-term clinical outcome of patients with chronic HDV [25].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Untitled

2016

Cent Asian J Med Sci

View full text Add to dashboard Cite

Objectives: Quantification of serum HBsAg has several clinical significances such as acting as a biomarker for the hepatitis D virus (HDV)-RNA level and necroinflammatory activity in HDV infection. The WFA+-M2BP is a new glyco-biomarker for liver fibrosis. The aim of this study was to compare the quantitative HBsAg and M2BPGi levels between groups of HBV infected patients with or without HDV infection. Methods: Totally, 112 consecutive HBsAg carriers with or without HDV infection (median age 36 vs 38) were enrolled in the study. Serum HBsAg and M2BPGi levels were measured using commercial tests. Results: Mean qHBsAg concentrations were 3.8 ±0.6 log IU/mL and 3.5 ±0.8 log IU/mL in the HDV positive and HDV negative HBsAg carriers, respectively (p = 0.02). Yet 45 patients out of 56 HDV positive patients have HBsAg level >2000 IU/mL whereas only 33 patients in the HBV mono infected group had concentrations this high. The mean M2BPGi was a 1.2 cut-off index (COI) in the HDV negative group vs. 2.1 COI in the HDV positive group (p <0.001). Conclusion: The qHBsAg level was higher in HDV positive patients compared with HDV negative subjects. But qHBsAg levels were higher in the HBeAg positive subjects despite the presence of HDV infection. The mean M2BPGi value in the HDV positive group was higher than in HDV negative subjects.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussioncontrasting

confidence: 42%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

2016

Cent Asian J Med Sci

View full text Add to dashboard Cite

show abstract

“…In HBeAg-positive CHD, HBV DNA levels are generally higher than HBeAg-negative CHD. However, serum HDV RNA is positive with high level (24,25). HBsAg levels do not directly correlate with serum HBV DNA level in HBeAg-negative CDH patients, however, HBsAg production is preserved (26).…”

Section: The Relationship Between Hbv Dna and Hdv Rna In Chd Infectionmentioning

confidence: 90%

Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Yurdaydın

Tabak

Kaymakoğlu

et al. 2017

Turk J Gastroenterol

Self Cite

View full text Add to dashboard Cite

Hepatitis D

Negro,

Lok

2023

JAMA

View full text Add to dashboard Cite

ImportanceHepatitis D virus (HDV) infection occurs in association with hepatitis B virus (HBV) infection and affects approximately 12 million to 72 million people worldwide. HDV causes more rapid progression to cirrhosis and higher rates of hepatocellular carcinoma than HBV alone or hepatitis C virus.ObservationsHDV requires HBV to enter hepatocytes and to assemble and secrete new virions. Acute HDV-HBV coinfection is followed by clearance of both viruses in approximately 95% of people, whereas HDV superinfection in an HBV-infected person results in chronic HDV-HBV infection in more than 90% of infected patients. Chronic hepatitis D causes more rapidly progressive liver disease than HBV alone. Approximately 30% to 70% of patients with chronic hepatitis D have cirrhosis at diagnosis and more than 50% die of liver disease within 10 years of diagnosis. However, recent studies suggested that progression is variable and that more than 50% of people may have an indolent course. Only approximately 20% to 50% of people infected by hepatitis D have been diagnosed due to lack of awareness and limited access to reliable diagnostic tests for the HDV antibody and HDV RNA. The HBV vaccine prevents HDV infection by preventing HBV infection, but no vaccines are available to protect those with established HBV infection against HDV. Interferon alfa inhibits HDV replication and reduces the incidence of liver-related events such as liver decompensation, hepatocellular carcinoma, liver transplant, or mortality from 8.5% per year to 3.3% per year. Adverse effects from interferon alfa such as fatigue, depression, and bone marrow suppression are common. HBV nucleos(t)ide analogues, such as entecavir or tenofovir, are ineffective against HDV. Phase 3 randomized clinical trials of bulevirtide, which blocks entry of HDV into hepatocytes, and lonafarnib, which interferes with HDV assembly, showed that compared with placebo or observation, these therapies attained virological and biochemical response in up to 56% of patients after 96 weeks of bulevirtide monotherapy and 19% after 48 weeks of lonafarnib, ritonavir, and pegylated interferon alfa treatment.Conclusions and RelevanceHDV infection affects approximately 12 million to 72 million people worldwide and is associated with more rapid progression to cirrhosis and liver failure and higher rates of hepatocellular carcinoma than infection with HBV alone. Bulevirtide was recently approved for HDV in Europe, whereas pegylated interferon alfa is the only treatment available in most countries.

show abstract

HBeAg‐positive hepatitis delta: virological patterns and clinical long‐term outcome

Abstract: HBV DNA levels are low in both HBeAg-negative and HBeAg-positive patients suggesting suppressive effects of HDV on HBV irrespective of the phase of HBV infection. The clinical long-term outcome of HBeAg-positive patients is not different to HBeAg-negative patients infected with the HDV.

Cited by 59 publications

References 46 publications

Untitled

Untitled

Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Hepatitis D

Contact Info

Product

Resources

About